CureVac Breaks Ground on New Mfg Facility for RNA Therapeutics
By
CureVac, a Tübingen, Germany-headquartered clinical-stage biopharmaceutical company focused on mRNA (messenger ribonucleic acid)-based drug development, has broken ground for an industrial-scale production facility at its headquarters. The GMP-compliant production facility…
Novartis to Acquire Advanced Accelerator Applications for $3.9 Billion
By
As part of a move to strengthen its oncology portfolio, Novartis has signed a memorandum of understanding with Advanced Accelerator Applications (AAA), a Saint-Genis-Pouilly, France-headquartered radiopharmaceutical company, under which Novartis…